Navigation Links
ResMed Receives Permanent Injunction against APEX in Germany, Continues Enforcement of Patents in Europe
Date:7/28/2014

MUNICH, July 28, 2014 /PRNewswire/ -- ResMed (NYSE: RMD), an innovator and pioneer in developing products for the treatment of sleep-disordered breathing and other chronic respiratory conditions, has won a permanent injunction in Germany against Taiwanese medical device manufacturer APEX Medical Corp. (APEX), prohibiting sales of infringing headgear used on APEX WiZARD 210 and 220 masks.  The judgment was entered by the Regional District Court in Munich, is appealable, and applies throughout Germany. 

The permanent injunction continues a preliminary injunction that was entered by the same court on Nov. 12, 2013.  The court rejected APEX's request to stay the injunction and its challenge to the validity of ResMed's patent.  The judgment also requires APEX to forfeit its inventory of infringing products, to report on its sales of the infringing products, and to pay damages to ResMed.ResMed has also filed separate patent infringement lawsuits in the same court seeking damages and permanent injunctions to stop infringement of other ResMed patents. The trials of those cases will occur in the fall of 2014.  The additional accused products are:

  • The APEX iCH and XT Fit CPAP devices
  • The APEX WiZARD 210 and WiZARD 220 masks
  • "ResMed has a global business built on its investment in research and developments, resulting in products sold worldwide that excel in performance, quality and comfort," said David Pendarvis, ResMed global general counsel and chief administrative officer. "We will continue to defend our investment in intellectual property and pursue all legal remedies to prevent infringement in any country where that infringement exists."

    About ResMed: ResMed changes lives by developing, manufacturing and distributing medical equipment for treating, diagnosing, and managing sleep-disordered breathing, COPD, and other chronic diseases. We develop innovative products and solutions to improve the health and quality of life of those who suffer from these conditions, and we work to raise awareness of the potentially serious health consequences of untreated sleep-disordered breathing. For more information on ResMed, visit www.resmed.com.  Contacts:
    For News Media For InvestorsGretchen Griswold

    Agnes LeeDirector, Global Corporate CommunicationsSenior Director, Investor RelationsO: 858-836-6789

    O: 858-836-5971news@resmed.com

    investorrelations@resmed.com


    '/>"/>
    SOURCE ResMed Inc.
    Copyright©2014 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. ITC Rules Redesigned APEX Humidifier Still Infringes ResMed Patents
    2. ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results
    3. ResMeds New Nasal Pillows System is Our Quietest Yet; Ultra-light AirFit P10 Packs Powerful Performance in Just over 1.5 Ounces
    4. ResMed Announces Conference Call And Webcast To Discuss Second Quarter 2014 Results
    5. BMC to protect its rights in patent fight with ResMed
    6. Apex reagiert energisch auf ResMed Patentklage
    7. ResMed Receives Injunctions against APEX and BMC in Germany, Continues Enforcement of Patents in Europe
    8. ResMed Inc. Announces Record Financial Results For The Quarter Ended September 30, 2013
    9. ResMeds New Nasal Mask Sets the Bar for Comfort and Performance
    10. ResMed Patent Infringement Case Against BMC Advances: International Trade Commission Agrees to Investigate
    11. Apex Fights Back Against ResMeds Patent Litigation
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/17/2017)... 17, 2017 According to a new market ... Particle Counters), Application (Cleanroom Monitoring, Contamination Monitoring of Liquids), and End ... by MarketsandMarkets, the market is expected to reach USD 330.6 Million ... of 3.7% from 2016 to 2021. ... ...
    (Date:2/17/2017)... , Feb. 17, 2017  Perrigo Company plc (NYSE, TASE: ... U.S. Food and Drug Administration for hydrocodone bitartrate and homatropine ... Hydrocodone bitartrate and homatropine methylbromide oral solution ... the symptomatic relief of cough in adults and children 6 ... months ending January 2017 were approximately $16 million.   ...
    (Date:2/17/2017)... NEW YORK , Feb. 17, 2017   ... other side effects allegedly associated with use of the ... Philadelphia Court of Common Pleas, ... a mass tort program. According to a notice posted ... scheduled to convene a meeting on March 9, 2017 ...
    Breaking Medicine Technology:
    (Date:2/17/2017)... ... February 17, 2017 , ... The Alliance Healthcare ... designed to further positively impact the health and wellness of our community in ... it our duty to seriously consider releasing our assets beyond our 5% targeted ...
    (Date:2/17/2017)... (PRWEB) , ... February 17, 2017 , ... ... Steps to Prevent a Warning Letter, **An FDAnews Webinar**, Feb. 23, 2017 — ... Do manufacturers distinguish between corrective action (CA) and preventive action (PA)? , The ...
    (Date:2/17/2017)... , ... February 17, 2017 , ... ... operations executives and focusing on all facets of clinical trial planning and management. ... , patient engagement, and more. In addition, attendees stopping by Pharmica’s booth were ...
    (Date:2/17/2017)... (PRWEB) , ... February 17, 2017 , ... ... services and financial planning assistance to families and business owners in and around ... a charity drive to help prevent all forms of domestic violence. , There ...
    (Date:2/16/2017)... ... 2017 , ... The Price Agency, a Jefferson County-based firm ... the Birmingham area, is announcing an ongoing charity event to help raise support ... son, Anius. , Anius is medically complex with diagnoses consisting and not limited ...
    Breaking Medicine News(10 mins):